Research programme: degenerative and metabolic disorder therapeutics - Prothena Corporation
Alternative Names: Islet amyloid polypeptide antibodies - ProthenaLatest Information Update: 30 Dec 2022
Price :
$50 *
At a glance
- Originator Neotope Biosciences
- Developer Neotope Biosciences; Prothena
- Class Eye disorder therapies; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Protein aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Alzheimer's disease; Metabolic disorders; Neurodegenerative disorders
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Alzheimer's disease in Ireland (Parenteral)
- 30 Dec 2022 Discontinued - Preclinical for Metabolic disorders in Ireland (Parenteral)
- 30 Dec 2022 Discontinued - Preclinical for Neurodegenerative disorders in Ireland (Parenteral)